In 2022, a study of 10 women diagnosedwith metastatic HER2+ breast cancer examined whether [64Cu]-DOTA-trastuzumab PET-CT could predict the response to trastuzumab-emtansine(T-DM1), an antibody-drug conjugate combining trastuzumab with thepotent cytotoxin DM1.148 Their conjugationis achieved via a noncleavable maleimidomethyl cyclohexane-1-carboxylate(MCC) thioether linker. Here, ERBB2 is linked to breast carcinoma.